Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
Stefaan
S
Van Gool
Steven
S
De Vleeschouwer
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D019317:Evidence-Based Medicine; D005909:Glioblastoma / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000639:trends; D010446:Peptide Fragments / Q000008:administration & dosage / Q000378:metabolism; D011379:Prognosis
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D010446:Peptide Fragments